Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.

MLA

Lowe, Stephen, et al. “Effects of a Novel MGlu₂/₃ Receptor Agonist Prodrug, LY2140023 Monohydrate, on Central Monoamine Turnover as Determined in Human and Rat Cerebrospinal Fluid.” Psychopharmacology, vol. 219, no. 4, Feb. 2012, pp. 959–70. EBSCOhost, https://doi.org/10.1007/s00213-011-2427-9.

APA

Lowe, S., Dean, R., Ackermann, B., Jackson, K., Natanegara, F., Anderson, S., Eckstein, J., Yuen, E., Ayan-Oshodi, M., Ho, M., McKinzie, D., Perry, K., & Svensson, K. (2012). Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid. Psychopharmacology, 219(4), 959–970. https://doi.org/10.1007/s00213-011-2427-9

Chicago

Lowe, Stephen, Robert Dean, Bradley Ackermann, Kimberley Jackson, Fanni Natanegara, Shelby Anderson, James Eckstein, et al. 2012. “Effects of a Novel MGlu₂/₃ Receptor Agonist Prodrug, LY2140023 Monohydrate, on Central Monoamine Turnover as Determined in Human and Rat Cerebrospinal Fluid.” Psychopharmacology 219 (4): 959–70. doi:10.1007/s00213-011-2427-9.